Skip to main content

Core value dossiers for medical technologies

Essential tool to support market access and marketing efforts through the lifecycle of the product

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Summary of the presentation of Oleg Borisenko at the Med Tech Forum’s session “Innovative Payment Schemes (IPSs) in Europe: springboard for innovation?”

Director of MTRC Oleg Borisenko participated in the session “Innovative Payment Schemes (IPSs) in Europe: springboard for innovation?” at the Med Tech Forum in Dublin on the 31st of May 2023.

The section was moderated by Rachele Busca (Director, HTA and Real-World Evidence, EMEACLA, Edwards Lifesciences), and panelists included Daniel Bamford (Deputy Director, Medtech and Digital, Innovation, Research and Life Sciences, NHS England) and Louisa Stüwe (Ministerial eHealth Delegation, Ministry of Health and Prevention, France).

Oleg presented the summary of the report on innovative payment schemes for medical technologies, commissioned in 2022 by the European industry association Med Tech Europe to MTRC.

We present a summary of the presentation below.

  • The primary objective of the 2022 project was to identify and map all the pathways that enable patient access to medical technologies and procedures, including the Innovative Payment Schemes in European countries. The objective of the project was not to assess/perform a ranking of the innovative payment schemes and initiatives/actions
  • The project included different types of medical technologies (procedures, devices, IVD tests, digital technologies) across all clinical settings (hospital, ambulatory, home care)
  • An innovative payment scheme was defined as a bilateral (e.g., payer & manufacturer) or multi-lateral (e.g., payer, provider, manufacturer) agreement that provides temporary coverage and/or funding to enable patient access to medical technologies and procedures outside the general reimbursement and funding frameworks
  • Across 32 countries, 21 innovative payment schemes were identified (they were present only in Austria, Belgium, England, France, Germany, the Netherlands, Spain, and Switzerland)
  • The largest number of schemes were identified in France (n=6), Germany (n=4) and England (n=3)
  • In 12 out of 21 schemes, direct payment is provided for a medical technology / procedure. The direct payment was defined as the availability of a specific tariff/fee for a procedure or device
  • Coverage with evidence development (CED) was the key form of innovative payment schemes in Europe (18 out of 21 schemes). Some of the CED schemes are the result of the regular reimbursement or funding process, while others represent a stand-alone activity
  • Unconditional innovation payment is rare in Europe (only three schemes were identified, including the Med Tech Funding Mandate in England, Transitional Coverage of Medical Devices (Prise en Charge Transitoire) in France and NUB in Germany
  • The majority of innovative payment schemes (18 out of 21) offer support for a small number (<15 annually) of technologies / procedures
  • The majority (67%) of innovative payment schemes allow for direct application by the industry or physicians / providers / researchers

You can see additional information on the website of Med Tech Europe.